Redmile Group LLC lowered its stake in Xencor, Inc. (NASDAQ:XNCR) by 25.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,187,494 shares of the biopharmaceutical company’s stock after selling 405,032 shares during the period. Xencor accounts for 1.5% of Redmile Group LLC’s portfolio, making the stock its 25th largest position. Redmile Group LLC owned 2.53% of Xencor worth $25,068,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently modified their holdings of the stock. FMR LLC increased its holdings in shares of Xencor by 77.7% in the second quarter. FMR LLC now owns 6,690,258 shares of the biopharmaceutical company’s stock valued at $141,232,000 after purchasing an additional 2,924,510 shares in the last quarter. Vanguard Group Inc. boosted its stake in Xencor by 5.6% in the second quarter. Vanguard Group Inc. now owns 1,701,209 shares of the biopharmaceutical company’s stock valued at $35,913,000 after acquiring an additional 90,094 shares during the last quarter. State Street Corp boosted its stake in Xencor by 11.1% in the second quarter. State Street Corp now owns 1,103,455 shares of the biopharmaceutical company’s stock valued at $23,295,000 after acquiring an additional 110,474 shares during the last quarter. Northern Trust Corp boosted its stake in Xencor by 6.6% in the second quarter. Northern Trust Corp now owns 498,616 shares of the biopharmaceutical company’s stock valued at $10,527,000 after acquiring an additional 30,715 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Xencor by 8.0% in the first quarter. Geode Capital Management LLC now owns 367,230 shares of the biopharmaceutical company’s stock valued at $8,783,000 after acquiring an additional 27,099 shares during the last quarter. 76.92% of the stock is owned by institutional investors and hedge funds.
In other Xencor news, major shareholder John S. Stafford III purchased 25,000 shares of the company’s stock in a transaction on Wednesday, August 16th. The stock was acquired at an average cost of $20.96 per share, for a total transaction of $524,000.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder John S. Stafford III bought 41,016 shares of the stock in a transaction dated Tuesday, August 22nd. The shares were purchased at an average price of $19.69 per share, with a total value of $807,605.04. The disclosure for this purchase can be found here. Insiders acquired a total of 215,551 shares of company stock valued at $4,386,916 over the last 90 days. 4.14% of the stock is currently owned by corporate insiders.
A number of equities analysts have issued reports on the stock. Zacks Investment Research cut shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Canaccord Genuity reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Xencor in a research note on Tuesday, August 8th. ValuEngine raised shares of Xencor from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, BidaskClub cut shares of Xencor from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $28.00.
Shares of Xencor, Inc. (NASDAQ:XNCR) remained flat at $23.76 during midday trading on Tuesday. The company’s stock had a trading volume of 52,569 shares. Xencor, Inc. has a 52 week low of $18.45 and a 52 week high of $29.38. The firm has a 50 day moving average price of $22.67 and a 200 day moving average price of $22.46. The firm’s market cap is $1.11 billion.
Xencor (NASDAQ:XNCR) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.10. The company had revenue of $13.34 million during the quarter, compared to analyst estimates of $8.15 million. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%. Equities analysts expect that Xencor, Inc. will post ($1.17) earnings per share for the current fiscal year.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with our FREE daily email newsletter.